Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Anemia Clinical Trials

A listing of Anemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (49) clinical trials

Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease

PROTOCOL OUTLINE: Patients are treated with intravenous glucocerebrosidase every 2 weeks. The dose is based on clinical severity of disease and response to therapy.

Phase

Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias

Nonmyeloablative allogeneic peripheral blood stem cell (PBSC) transplants are currently being investigated in phase I/II trials assessing engraftment, efficacy, and toxicity at a number of transplant centers. Preliminary data have shown a high rate of complete donor engraftment with a relatively low toxicity profile. The decreased risk of transplant-related complications ...

Phase

L-leucine in Diamond Blackfan Anemia Patients

Experimental: one arm L-leucine , dose- 700mg/m2 , per os, 3 time a day, 6 months

Phase

A Phase II Trial of Regadenoson in Sickle Cell Anemia

If you are willing to participate in this research study you will be asked to undergo some screening tests and procedures to confirm your eligibility. Many of these tests and procedures are likely to be part of regular sickle cell anemia care and may be done even if it turns ...

Phase

EXTEND EXpanding Treatment for Existing Neurological Disease

Hydroxyurea treatment: Participants will be treated with open-label hydroxyurea, available as capsules (200 ,g, 300 mg, 400 mg, or 500 mg), or as a liquid formulation (100 mg/mL). Hydroxyurea will be administered once daily by mouth. Participants will be monitored monthly to maximum tolerated dose and quarterly thereafter with periodic ...

Phase

Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases

OBJECTIVES: Primary - Determine the impact of the use of umbilical cord blood as a source of hematopoietic stem cells for children with life-threatening oncologic, hematologic, or genetic/metabolic disorders in need of a stem cell transplant. - Compare the incidence of graft-versus-host disease in patients receiving cord blood transplants in ...

Phase

Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA)

Anti-thymocyte globulin (ATG) has been used in severe aplastic anemia as a part of the conditioning regimen. Among the many kinds of ATG preparations, thymoglobulin had been found to be more effective in preventing graft versus host disease (GVHD) and rejection of organ transplants. As the fludarabine based conditioning regimens ...

Phase

Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure

OBJECTIVES: Primary - Determine the safety of alemtuzumab and low-dose cyclosporine, as defined by occurrence of adverse effects, in patients with severe aplastic anemia or single lineage acquired marrow failure. - Determine the efficacy of this regimen, in terms of overall survival, hematological response (partial and complete response, including time ...

Phase

Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases

OBJECTIVES: Primary - Determine the 1-year survival of patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine, cyclophosphamide, and fractionated total-body irradiation. Secondary - Determine the incidence of transplant-related mortality at 6 months after UCBT. - Evaluate the pattern of chimerism ...

Phase

Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia

OBJECTIVES: Primary - Determine the incidence of engraftment, defined as achieving donor-derived neutrophil count > 500/mm³ by day 42, in infants with high-risk acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndromes treated with a non-irradiation containing myeloablative conditioning regimen comprising busulfan, fludarabine, and melphalan followed by double umbilical cord ...

Phase